CEBPZ and acute myeloid leukemia: However, despite this overall favorable categorization, approximately 30~40% of CBF-AML patients still experience relapse with median follow-up time of 3.5 years [9], which highlights the molecular heterogeneity within this disease category and underscores the importance of refined prognostic stratification.